Comparison of mealtime pramlintide, insulin, or a combination of both, when added to basal insulin treatment in patients with type 2 diabetes

被引:0
|
作者
Karounos, D. [1 ,2 ]
Pencek, R. [3 ]
Huang, W. [3 ]
Miller, S. [3 ]
Lutz, K. [3 ]
Porter, L. [3 ]
机构
[1] Lexington VA Med Ctr, Lexington, VA USA
[2] Univ Kentucky, Coll Med, Lexington, KY USA
[3] Amylin Pharmaceut Inc, San Diego, CA USA
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
912
引用
收藏
页码:S358 / S358
页数:1
相关论文
共 50 条
  • [1] Comparison of Mealtime Pramlintide, Insulin, or a Combination of Both, When Added to Basal Insulin Treatment in Patients with Type 2 Diabetes
    Karounos, Dennis
    Pencek, Rich
    Huang, Wenying
    Miller, Stephan
    Lutz, Karen
    Porter, Lisa
    [J]. DIABETES, 2009, 58 : A32 - A32
  • [2] Pramlintide or mealtime insulin added to basal insulin treatment in patients with type 2 diabetes
    Riddle, M.
    Pencek, R.
    Charenkavanich, S.
    Lutz, K.
    Porter, L.
    Wilhelm, K.
    [J]. DIABETOLOGIA, 2008, 51 : S407 - S408
  • [3] Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
    Riddle, Matthew
    Pencek, Richard
    Charenkavanich, Supoat
    Lutz, Karen
    Wilhelm, Ken
    Porter, Lisa
    [J]. DIABETES CARE, 2009, 32 (09) : 1577 - 1582
  • [4] Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study
    Pencek, R.
    Roddy, T.
    Peters, Y.
    De Young, M. B.
    Herrmann, K.
    Meller, L.
    Nguyen, H.
    Chen, S.
    Lutz, K.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (06): : 548 - 551
  • [5] A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients
    Pala, L.
    Mannucci, E.
    Dicembrini, I.
    Rotella, C. M.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 78 (01) : 132 - 135
  • [6] Mealtime amylin replacement with pramlintide markedly reduced postprandial glucose excursions when added to insulin lispro in patients with type 1 or type 2 diabetes
    Weyer, C
    Kim, D
    Burrell, T
    Wang, Y
    Kornstein, J
    Bicsak, T
    Fineman, M
    Ruggles, J
    Schwartz, S
    Kolterman, O
    [J]. DIABETES, 2003, 52 : A16 - A16
  • [7] Pramlintide improved glycemic control and reduced body weight in patients with type 2 diabetes treated with basal insulin (without mealtime insulin) and a thiazolidinedione
    Lorenzi, Gayle
    Frias, Juan
    Lutz, Karen
    Kesty, Nicole
    Zhang, Bei
    Kolterman, Orville
    [J]. DIABETES, 2007, 56 : A147 - A147
  • [8] Effect of pramlintide treatment on markers of cardiovascular risk in patients with type 2 diabetes using basal insulin
    Lush, C.
    Zhang, B.
    Maggs, D.
    Darsow, T.
    Kolterman, O.
    [J]. DIABETOLOGIA, 2007, 50 : S514 - S514
  • [9] Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs
    Peyrot, Mark
    Rubin, Richard R.
    Polonsky, William H.
    Best, Jennie H.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1047 - 1054
  • [10] Mealtime amylin replacement with pramlintide markedly improves postprandial glucose excursions when added to insulin lispro in patients with type 2 diabetes: a dose-timing study
    Maggs, D
    Weyer, C
    Crean, J
    Wang, Y
    Burrell, T
    Fineman, M
    Kornstein, J
    Schwartz, S
    Guiterrez, M
    Kolterman, O
    [J]. DIABETOLOGIA, 2002, 45 : A264 - A265